Patents by Inventor Moritz RAPP

Moritz RAPP has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11723922
    Abstract: The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) ?? T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 15, 2023
    Assignee: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN
    Inventors: Sebastian Kobold, Stefan Endres, Moritz Rapp, Simon Grassmann
  • Publication number: 20220227878
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: December 21, 2021
    Publication date: July 21, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Harald DUERR, Christian KLEIN, Pablo UMANA, Alexander BUJOTZEK, Joerg ZIELONKA, Christine TRUMPFHELLER, Moritz RAPP, Marine LE CLECH
  • Patent number: 11242396
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Harald Duerr, Christian Klein, Pablo Umana, Alexander Bujotzek, Joerg Zielonka, Christine Trumpfheller, Moritz Rapp, Marine Le Clech
  • Publication number: 20210292426
    Abstract: The invention relates to novel bispecific antigen binding molecules with trivalent binding to CD40 and monovalent binding to a target cell antigen and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: March 31, 2021
    Publication date: September 23, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald DUERR, Moritz RAPP, Christine TRUMPFHELLER, Pablo UMANA
  • Publication number: 20210188992
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: February 18, 2021
    Publication date: June 24, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Alexander BUJOTZEK, Harald DUERR, Guy GEORGES, Christian KLEIN, Stephane LECLAIR, Moritz RAPP, Eva Carina SUM, Christine TRUMPFHELLER, Pablo UMAÑA
  • Publication number: 20200190207
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 30, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Harald DUERR, Christian KLEIN, Pablo UMANA, Alexander BUJOTZEK, Joerg ZIELONKA, Christine TRUMPFHELLER, Moritz RAPP, Marine LE CLECH
  • Publication number: 20180340030
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: April 3, 2018
    Publication date: November 29, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Alexander BUJOTZEK, Harald DUERR, Guy GEORGES, Christian KLEIN, Stephane LECLAIR, Moritz RAPP, Eva Carina SUM, Christine TRUMPFHELLER, Pablo UMAÑA
  • Publication number: 20180256645
    Abstract: The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) ?? T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.
    Type: Application
    Filed: October 14, 2016
    Publication date: September 13, 2018
    Inventors: Sebastian KOBOLD, Stefan ENDRES, Moritz RAPP, Simon GRASSMANN